SEC Comment Letter for Enveric Biosciences, Inc. (ENVB) (CIK 0000890821) (ENVB) — Oct 19, 2018
Enveric Biosciences, Inc. (ENVB) (CIK 0000890821)
Date: Oct. 19, 2018 · CIK: 0000890821 · Accession: 0000000000-18-032914
AI Filing Summary & Sentiment
File numbers found in text: 333-227011
Show Raw Text
October 19, 2018
Brent Kelton
Chief Executive Officer
AMERI Holdings, Inc.
5000 Research Court, Suite 750
Suwanee, Georgia 30024
Re:AMERI Holdings, Inc.
Registration Statement on Form S-1
Response Dated October 18, 2018
File No. 333-227011
Dear Mr. Kelton:
We have reviewed your October 18, 2018 response to our comment letter and have the
following comments. In some of our comments, we may ask you to provide us with information
so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments. Unless we note
otherwise, our references to prior comments are to comments in our October 17, 2018 letter.
Response Letter submitted October 18, 2018
Private Placement, page 3
1.We note your response to prior comment 1. However, the number of shares indicated in
your table on page 35 as offered for resale if no adjustments are made does not appear to
reconcile to your disclosure regarding the number of securities sold. Please revise as
appropriate.
2.Revise your disclosure regarding the total number of shares that could become issuable
under the agreements to clarify how you calculated those numbers. Address the number
of shares that do not underlie warrants, the number of shares underlying the pre-funded
FirstName LastNameBrent Kelton
Comapany NameAMERI Holdings, Inc.
October 19, 2018 Page 2
FirstName LastName
Brent Kelton
AMERI Holdings, Inc.
October 19, 2018
Page 2
warrants, and the number of shares underlying the warrants that are not pre-funded
separately.
Please contact Tim Buchmiller at (202) 551-3635 or Russell Mancuso, Branch Chief, at
(202) 551-3617 with any questions.
Sincerely,
Division of Corporation Finance
Office of Electronics and Machinery
cc: Adam W. Finerman, Esq.